Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. (CacheMire)
Cross-sectional, Multicentric, Non-interventional Study to Assess the Frequency and the Management of Cachexia and Associated Symptoms in Patients With Non-small Cell Lung Cancer.
調査の概要
詳細な説明
This is a cross-sectional, non-interventional, European (France and Belgium), multicentric prevalence study, conducted on a representative population of 500 patients with NSCLC, to assess the frequency and the management of cachexia and associated symptoms.
The study will be conducted in accordance with the professional code of ethics and the good epidemiological practices guidelines developed by the ADELF (the Association of French-Speaking Epidemiologists) and in accordance with the STROBE recommendations for the drafting of reports and publications related to the study.
The information will be collected during a single visit to the oncologist/lung specialist as part of the usual patient management of his/her lung cancer. The physician will explain the purpose of the study to the patient with an information form specific to the study and will inform him/her of the option to refuse or withdraw from participation. The patient information form in France or a specific consent form in Belgium will be signed by the patient and a copy will be given to him/her (the original will be kept by the physician).
This study does not require any additional specific data. Data will come from the medical file and from the routine disease management. Furthermore, the following self-completion questionnaires will be proposed to patients: Visual analogue scale for dietary intake (dietary intake VAS), assessment of the concerns associated with the anorexia/cachexia (Anorexia-Cachexia module of the Functional Assessment of Anorexia/Cachexia Therapy [FAACT] questionnaire), quality of life (EORTC QLQ-C30), and assessment of physical activity (IPAQ, International Physical Activity Questionnaire). Abdominal CT-scan, if available, will be collected for assessment of skeletal muscle mass index at L3.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Paris、フランス、92042
- Chugai Pharma France
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Patient 18 years of age and older
- Patient with NSCLC
- Patient who has been informed of the study and who has signed a patient information leaflet for France or an informed consent for Belgium
- Patient able to complete a self-assessment questionnaire
Exclusion Criteria:
- Patient unable to consent and/or unable to sign the patient information form in France or an informed consent in Belgium
- Patient with a complete resection of an early stage NSCLC
- History of head and neck cancer
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:断面図
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Frequency of Cachexia According to Modified Fearon Criteria
時間枠:Day1
|
Percentage of NSCLC patients with a cachexia according to Fearon criteria modified for the stages of pre-cachexia and refractory cachexia in order to classify all the featured cases without ambiguity. A patient was considered to have cachexia if he/she had:
In the 3 cases defined above, patient should not have entered the refractory cachexia stage, which was defined as: ECOG performance score of 3 or 4 and a low survival expectancy as defined by Martin et al. (J Clin Oncol 2015) (BMI <20 kg/m² and weight loss ≥ 6%) or (20 ≤ BMI ≤ 21.9 kg/m² and weight loss ≥ 11%) or (22 kg/m² ≤ BMI and weight loss ≥ 15%). |
Day1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population
時間枠:Day 1
|
Percentage of the different stages of cachexia at inclusion. The different stages of cachexia used the following classification:
|
Day 1
|
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC.
時間枠:Day 1
|
Percentage of the different stages of cachexia at inclusion according to the NSCLC stage
|
Day 1
|
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC.
時間枠:Day 1
|
Percentage of the different stages of cachexia according to the NSCLC histology
|
Day 1
|
|
Frequency of Sarcopenia in the General NSCLC Patients With Cachexia
時間枠:Day 1
|
Percentage of patients with sarcopenia in the general NSCLC patients with cachexia
|
Day 1
|
|
Frequency of Sarcopenia With no Clinical Significant Weight Loss in the General NSCLC Patients With Pre-cachexia
時間枠:Day 1
|
Percentage of patient with sarcopenia and no clinical significant weight loss (sarcopenia and WL< 2%) in the general NSCLC patients with pre-cachexia:
|
Day 1
|
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC.
時間枠:Day 1
|
Percentage of the different stages of cachexia according to the molecular abnormalities associated with NSCLC:
|
Day 1
|
|
Frequency of the Different Stages of Cachexia According to the Number of Treatments Received.
時間枠:Day 1
|
NSCLC patients.
84 patients with missing data
|
Day 1
|
|
Frequency of the Different Stages of Cachexia According to the Types of Treatments Received.
時間枠:Day 1
|
Stage of cachexia at inclusion according to the type of treatments received (surgery, radiotherapy, chemotherapy, targeted therapies).
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State
時間枠:Day 1
|
• Nutritional state according to the different stages of cachexia The variables used will be: serum albumin levels, serum pre-albumin levels, BMI and weight.
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose
時間枠:Day 1
|
Blood glucose abnormalities according to the different stages of cachexia at inclusion
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale
時間枠:Day 1
|
Dietary Intake Visual Analog Scale (Dietary intake VAS): The question "Could you indicate the amount you currently eat, placing a vertical mark on the line between "nothing at all" and "as usual"?
".
Depending on the location of the patient mark on the scale, a score of between 0 ("nothing at all") and 10 ("as usual") will be allocated.
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT
時間枠:Day 1
|
Score of the 12-question AC/S module (Anorexia-Cachexia module) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire assessing anorexia and cachexia: the AC/S module of the FAACT questionnaire consists of 12 questions to assess over the last 7 days quality of life, related to anorexia or cachexia.
The score ranges between 0 and 48, the higher the score, the higher the quality of life.
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio
時間枠:Day 1
|
neutrophil/lymphocyte ratio
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP
時間枠:Day 1
|
CRP level
|
Day 1
|
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen
時間枠:Day 1
|
fibrinogen level
|
Day 1
|
|
Description of the Quality of Life Associated With the Different Stages of Cachexia.
時間枠:Day 1
|
Quality of life has been analysed using scores from the functional scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 items (EORTC QLQ-C30 questionnaire): score ranging from 0 (malfunction) to 100 (healthy level of functioning) for the following parameters : physical, role, cognitive, emotional and social scales
|
Day 1
|
|
Description of the Level of Physical Activity Associated With the Different Stages of Cachexia.
時間枠:Day 1
|
Three levels of physical activity are defined:
Corresponds to one of the following 2 criteria:
|
Day 1
|
|
Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms
時間枠:Day 1
|
Pharmacological treatment of cachexia or associated symptoms: Yes / No
|
Day 1
|
|
Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms
時間枠:Day 1
|
Non-pharmacological treatment of cachexia or associated symptoms: Y/N
|
Day 1
|
|
Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments
時間枠:Day 1
|
Treatments with systemic corticosteroids, anti-inflammatory drugs, Omega 3 fatty acids: Yes/No
|
Day 1
|
|
Number of Participants With Diabetes Treatments
時間枠:Day 1
|
Diabetes treatments : Yes/No
|
Day 1
|
|
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia
時間枠:Day 1
|
|
Day 1
|
|
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia
時間枠:Day 1
|
|
Day 1
|
|
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition
時間枠:Day 1
|
|
Day 1
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディディレクター:Luz Bobadilla, MD、Chugai Pharma France
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CPF-ANA-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。